The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I study of vincristine, irinotecan, and 131I-MIBG for patients with relapsed or refractory neuroblastoma: A New Approach to Neuroblastoma Therapy (NANT) study.
S. G. DuBois
No relevant relationships to disclose
L. Chesler
No relevant relationships to disclose
S. G. Groshen
No relevant relationships to disclose
R. Hawkins
No relevant relationships to disclose
F. Goodarzian
No relevant relationships to disclose
G. A. Yanik
No relevant relationships to disclose
C. F. Stewart
No relevant relationships to disclose
Y. P. Mosse
No relevant relationships to disclose
J. M. Maris
No relevant relationships to disclose
J. Villablanca
No relevant relationships to disclose
K. K. Matthay
No relevant relationships to disclose